Results 161 to 170 of about 188,791 (289)

Anti‐NMDA receptor autoimmune encephalitis associated with ovarian teratoma: A case series and literature review

International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 23-30, April 2025.
Abstract Autoimmune encephalitis is a group of disorders characterized by symptoms of dysfunction of the limbic and extra‐limbic systems that occur in association with antibodies against intracellular antigens, synapses, or proteins located on the surface of nerve cells. Anti‐NMDA (N‐methyl‐D‐aspartate) receptor encephalitis was first described in 2007
Pham Ba Nha, Nguyen Phuong Tu, Nguyen Viet Ha, Duong Thi Thu Hien, Nguyen Thi Thu Phuong, Nguyen Anh Son, Nguyen Tien Hoang   +6 more
wiley   +1 more source

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma [PDF]

, 2020
al., et, Bartlett, Nancy L., Cashen, Amanda, Edwin, Natasha, Ghobadi, Armin, Kahl, Brad, Mehta-Shah, Neha, Merryman, Reid W.   +7 more
core   +1 more source

The “5L” framework of diagnostic reasoning: A stepwise scaffold to support clinician educators

Journal of Hospital Medicine, EarlyView.
Abstract Diagnostic reasoning (DR) is a core clinical skill, yet its teaching remains variable. We introduce the “5L” framework as a bedside teaching scaffold that gives educators and learners a shared, stepwise set of prompts for DR during individual encounters. By asking, “What's Lethal? What's Likely? What's Logical? What's Lurking?
Olivia Brumfield, Amal Mohamed, Shuhan He, Cory Rohlfsen   +3 more
wiley   +1 more source

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle, Claire Abasq‐Thomas, Claire Bocciarelli, Amélie Bourhis, Marina Alexandre, Belen Eguia, Laurent Misery, Numa Deydier   +7 more
wiley   +1 more source

Anti-Sez6L2 antibody-associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy. [PDF]

Neurol Sci
Gao Y, Duan R.
europepmc   +1 more source

Precision medicine in thrombotic thrombocytopenic purpura: a narrative review. [PDF]

Ther Adv Hematol
Al-Shibly R, Ghasoub R, AlRasheed M, AlTourah L, Al-Eisa T, Yassin MA.   +5 more
europepmc   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source